SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT00270556

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Phase II, Open-Label,Randomised, Comparator Study of Substitution w/Tenofovir or Abacavir in HIV-1 Infected Individuals, w/Viral Load Less 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of HAART.

This 48 week study is designed to compare the substitution of the thymidine analogues zidovudine (ZDV) or stavudine (D4T) with either tenofovir DF or abacavir, in patients treated with highly active antiretroviral therapy (HAART), and show improved outcomes on total limb fat mass, improved body shape by dual energy x-ray absorptiometry (DEXA) and computed tomography (CT) scans and improved cholesterol and tryglicerides.

NCT00270556 HIV

2 Interventions

Name: tenofovir disoproxil fumarate

Type: Drug

Name: Abacavir

Type: Drug

There is one SNP


1 K65R

Subjects with no known K65R, 69S mutations or 3 or more thymidine analogue mutations. --- K65R ---

HPO Nodes